Funded Projects

We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.

People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition. 

We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.

Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals. 

In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.

This team is developing a small molecule that targets a voltage-gated ion channel within the inner ear for the symptomatic relief of peripheral vertigo attacks. They will use their Neuroscience:Translate award to further develop this molecule to restore normal function and improve activities of daily living for patients experiencing peripheral vertigo.

This team has identified a promising protein-based therapeutic to improve stroke recovery.  The team will use the Neuroscience:Translate award to identify key components of this protein to maximize its therapeutic potential for stroke treatments.

This team recently identified a selective biomarker of inflammation-promoting immune cells in the central nervous system. They will use their Neuroscience:Translate award to develop non-invasive molecular imaging strategies to distinguish between harmful (pro-inflammatory) and helpful (anti-inflammatory) immune cells in patients with Multiple sclerosis (MS).

This team has developed a new therapy for patients with spinal cord injury, involving injection into the spinal cord of patient-derived stem cells within an engineered protective gel. They will use their Neuroscience:Translate award to further test and develop this novel therapy in preparation for first-in-human clinical trials. 

This team recently discovered that a small molecule they had originally developed to treat Parkinson’s disease can also reduce the volume of glioblastoma tumors – the most common form of aggressive brain tumor — by targeting the mitochondrial protein Miro1. They will use their Neuroscience:Translate award to study the mechanisms of the compound’s anti-tumor action and prepare to apply for investigational-new-drug status to move this discovery toward the clinic.